A Phase 2 interventional study of 50 mg AP1189 and AP1189 in Rheumatoid Arthritis, sponsored by SynAct Pharma Aps. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-10.
Sponsored by SynAct Pharma Aps · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Arthritis, Rheumatoid with a site in Denmark — 14 open to participants now, 23 under way, 2 of them phase 3. Arthritis, Rheumatoid · Denmark.
Among the 99 studies in Arthritis, Rheumatoid with a site in Denmark, this one is the 45th largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 2, and was the 72nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →14 of the 99 studies in Arthritis, Rheumatoid with a site in Denmark are open now. Recruiting first, the newest first:
Klavs Würgler Hansen · Sites in Denmark
Ages 18+
Center for Clinical Research and Prevention · Sites in Denmark
Ages 18+
Hoffmann-La Roche · Sites in Denmark, United States, Argentina and 9 more countries
Ages 18+
Henning Bliddal · Sites in Denmark
Ages 18–65
Glostrup University Hospital, Copenhagen · Sites in Denmark
Ages 18–120
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 24 · Phase 4 8
First in 1998; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 70 interventional studies, 107 across the 29 observational. Of the 66 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 99 have an industry lead sponsor. The 10 most frequent:
SynAct Pharma Aps is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
SynAct Pharma Aps has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
4 of the studies in Arthritis, Rheumatoid with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924270Odense University HospitalSafety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases | 2027-03-01 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT06533423Glostrup University Hospital, CopenhagenEffect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: The NISMA Trial | 2027-05-30 |
| NCT06583980The Danish Center for Expertise in RheumatologyINSELMA - a Randomised Controlled Trial | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Arthritis, Rheumatoid with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) > 22, who are to start up-titration with methotrexate.
A multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) > 22, who are to start up-titration with methotrexate.
The study will be conducted in two parts separated by an interim analysis.
Part 1: The subjects will be randomized in a 1:1:1 ratio into: .
INTERIM ANALYSIS
Part 2: All subjects will be randomized into either design 1, 2 or 3 based on data from the interim analysis.
The purpose of this study is to determine the safety and efficacy of 2 doses of AP1189 compared with placebo after 4 weeks of treatment.
Inclusion Criteria:
Exclusion Criteria:
Exclusion criteria that only applies for Norway
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
Drug: 50 mg AP1189
100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
Drug: AP1189
Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
Drug: Placebo
50 mg AP1189 powder in bottle
Also known as: AP1189
100 mg AP1189 powder in bottle
Placebo powder in bottle
Change in Clinical Disease Activity Index (CDAI)
The change in CDAI from severe (CDAI \> 22) to moderate (CDAI \<= 22) after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity)
Time frame: 4 weeks
Change in Clinical Disease Activity Index (CDAI)
The change in CDAI after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity). The CDAI score range is from 0 - 76, whereas a score of: ≤2.8 means Remission \>2.8 and ≤10 means Low Disease Activity \>10 and ≤22 means Moderate Disease Activity \>22 means High Disease Activity For the purpose of this study, a decrease in CDAI (improvement) is reported as - xx.xx).
Time frame: 4 weeks
ACR (American College of Rheumatology) Response
Proportion of subjects achieving a response assessed by ACR20. The ACR response rate ACR20 is defined as ≥20% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.
Time frame: 4 weeks
ACR (American College of Rheumatology) Response
Proportion of subjects achieving a response assessed by ACR50. The ACR response rate ACR50 is defined as ≥50% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.
Time frame: 4 weeks
ACR (American College of Rheumatology) Response
Proportion of subjects achieving a response assessed by ACR70. The ACR response rate ACR70 is defined as ≥70% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.
Time frame: 4 weeks
| Milestone | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| Started | 35 | 36 | 34 |
| Completed | 33 | 34 | 32 |
| Not completed | 2 | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
The change in CDAI from severe (CDAI \> 22) to moderate (CDAI \<= 22) after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity)
| Participants | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| Change in Clinical Disease Activity Index (CDAI) | 18 | 17 | 12 |
The change in CDAI after 4 weeks treatment compared to baseline. CDAI is calculated as a sum of: * SJC (28): Number of Swollen 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees); * TJC (28): Number of Tender 28-Joint Count (shoulders, elbows, wrists, MCPs, PIPs including thumb IP, knees) * PGA: Patient Global Disease Activity (patient's self-assessment of overall RA disease activity on a scale 0-100, where 100 is maximal activity) * IGA: Physician's Global Disease Activity (evaluator's assessment of the subject's overall RA disease activity on a scale 0-100, where 100 is maximal activity). The CDAI score range is from 0 - 76, whereas a score of: ≤2.8 means Remission \>2.8 and ≤10 means Low Disease Activity \>10 and ≤22 means Moderate Disease Activity \>22 means High Disease Activity For the purpose of this study, a decrease in CDAI (improvement) is reported as - xx.xx).
| Calculated score | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| Change in Clinical Disease Activity Index (CDAI) | -11.97 ± 8.74 | -15.52 ± 12.70 | -9.33 ± 10.58 |
Proportion of subjects achieving a response assessed by ACR20. The ACR response rate ACR20 is defined as ≥20% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.
| Participants | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| ACR (American College of Rheumatology) Response | 11 | 20 | 10 |
Proportion of subjects achieving a response assessed by ACR50. The ACR response rate ACR50 is defined as ≥50% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.
| Participants | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| ACR (American College of Rheumatology) Response | 2 | 8 | 4 |
Proportion of subjects achieving a response assessed by ACR70. The ACR response rate ACR70 is defined as ≥70% improvement in swollen and tender joint counts (SJC/TJC) and 3 of the following 5 assessments: Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Pain, Health Assessment Questionnaire - Disability Index or C-Reactive Protein. Proportion in the context of this protocol refers to number of participants.
| Participants | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| ACR (American College of Rheumatology) Response | 0 | 4 | 1 |
Collected over All Adverse Event (AE)s were collected starting from the time of signed informed consent and until the final visit (End of Study/Early Termination visit) had occurred. Any AE that was ongoing at the final visit was followed until resolution or until four weeks after the study drug administration, whichever came first.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50 mg AP1189 | 0/35 (0%) | 0/35 (0%) | 14/35 (40%) |
| 100 mg AP1189 | 0/36 (0%) | 0/36 (0%) | 16/36 (44.4%) |
| Placebo | 0/34 (0%) | 0/34 (0%) | 12/34 (35.3%) |
| Event | 50 mg AP1189 | 100 mg AP1189 | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 5/35 | 7/36 | 7/34 |
| Alanine aminotransferase increasedInvestigations | 6/35 | 0/36 | 3/34 |
| HeadacheNervous system disorders | 2/35 | 5/36 | 0/34 |
| GGT increasedInvestigations | 3/35 | 0/36 | 3/34 |
| Arthritis rheumatoid aggravatedMusculoskeletal and connective tissue disorders | 3/35 | 2/36 | 1/34 |
| ConstipationGastrointestinal disorders | 2/35 | 3/36 | 0/34 |
| Aspartate aminotransferase increasedInvestigations | 2/35 | 0/36 | 2/34 |
| AnemiaBlood and lymphatic system disorders | 2/35 | 1/36 | 1/34 |
| ObstipationGastrointestinal disorders | 2/35 | 1/36 | 0/34 |
| DiarrheaInvestigations | 1/35 | 2/36 | 0/34 |
| Age, Categorical(Participants) | 50 mg AP1189 | 100 mg AP1189 | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 26 | 25 | 76 |
| >=65 years | 10 | 10 | 9 | 29 |
| Sex: Female, Male(Participants) | 50 mg AP1189 | 100 mg AP1189 | Placebo | Total |
|---|---|---|---|---|
| Female | 27 | 28 | 27 | 82 |
| Male | 8 | 8 | 7 | 23 |
| Ethnicity (NIH/OMB)(Participants) | 50 mg AP1189 | 100 mg AP1189 | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 |
| Not Hispanic or Latino | 35 | 36 | 32 | 103 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 50 mg AP1189 | 100 mg AP1189 | Placebo | Total |
|---|---|---|---|---|
| Norway | 2 | 0 | 1 | 3 |
| Denmark | 13 | 15 | 15 | 43 |
| Sweden | 3 | 3 | 1 | 7 |
| Moldova | 8 | 6 | 7 | 21 |
| Bulgaria | 9 | 12 | 10 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Nov 2021, 26 months.
Results were first posted in Jul 2024, 2 years 7 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 26 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resomelagon acetate
SynAct Pharma Aps